1/305
Looks like no tags are added yet.
Name | Mastery | Learn | Test | Matching | Spaced |
---|
No study sessions yet.
APRN prescribing role
Prescriptive authority for nurse practitioners also regulates prescribing rights beyond medications and controlled substances. These rights include therapeutic devices and services and are outlined in state practice laws and regulations and include Durable Medical Equipment (DME) such as wheelchairs, power scooters, hospital beds, portable oxygen equipment, handicap placards, etc. and medical services such as Physical Therapy (PT), Occupational Therapy (OT), home health services, etc. Prescriptive authority encompasses more than writing a prescription correctly. It requires adherence to ethical guidelines to ensure that patients are safeguarded from harm. Ethical prescribing starts with being well-informed about medications. Mechanism of action, efficacy, and safety are important considerations, as are a patient's distinct needs and circumstances, including the number of medications prescribed (Mitchell & Oliphant, 2016). Most patients receiving a prescription are taking other medications, whether prescription or over-the-counter. Appropriate selection, dosing, and duration of pharmaceutical agents are key to maximizing outcomes and minimizing adverse effects
benefits of full practice authority
Nurse practitioners have the autonomy to evaluate patients, diagnose, order and interpret tests, initiate and manage treatments and prescribe medications, including controlled substances without physician oversight
promoting positive outcomes through prudent prescribing practices
Administering medications and prescribing medications are two distinct processes. Prescription writing requires prudent and deliberate decision-making processes to maintain patient safety and reduce liability, including:
*documentation of a provider-patient relationship for the recipient of the prescribed medications
*documentation of a thorough history and physical examination for the recipient
*documentation of discussions regarding risk factors, side effects, or therapy options
*documentation of drug monitoring or titration plan, if applicable
*documentation of consultations, if any
avoidance of prescribing medications for self, family, or friends
Rational drug selection requires a logical approach that includes the formulation of a diagnosis based on clinical reasoning and the selection and monitoring of the most appropriate pharmacological treatment
Considerations include: Cost, guidelines, availability, interactions, side effects, allergies, hepatic/renal functions, need for monitoring, & special populations
Beer's Criteria
identifies drugs with a high likelihood of causing adverse effects in older adults. Accordingly, drugs on this list should generally be avoided in adults older than 65 years except when the benefits are significantly greater than the risks.
Pharmacodynamics
the study of the biochemical and physiologic effects of drugs on the body and the molecular mechanisms by which those effects are produced
Pharmacokinetics
the study of drug movement throughout the body
Pharmacogenomics
the study of how genes affect a person's response to drugs. The purpose of this is to combine the sciences of genomics and pharmacology to provide individualized, targeted, safe drug therapies to patients
CYP450 inducers
Inducers are xenobiotics (medications and environmental agents) that elevate CYP450 enzyme activity by increasing enzyme synthesis. This action leads to additional sites available for biotransformation. The increased number of sites enhances medication metabolism, decreasing the concentration of the "parent drug" while increasing metabolite production.
Inducers = Increase medication metabolism
(Carbamazepine, Rifampin, Alcohol, Phenytoin, Griseofulvin, Phenobarbital, Sulfonylureas)
CYP450 inhibitors
Inhibitors are medications that inhibit the metabolic activity of one or more of the CYP450 enzymes. Medications that inhibit an enzyme potentially slows that enzyme's activity or blocks the activity required for the metabolism of other medications, thereby increasing the levels of medications dependent on that particular enzyme for biotransformation. Inhibitors = decrease medication metabolism (Valproate, Isoniazid, Sulfonamides, Amiodarone, Chloramphenicol, Ketoconazole, Grapefruit Juice, Quinidine)
cultural influences in prescribing
The greatest concern surrounding race-based therapy has to do with genetic variability. We know there is great diversity within and among racial groups; therefore, a "one fits all" approach based on race is unwise. Still, we can use known associations to guide choices. For example, differences in metabolism between people with East Asian and European heritage are common. The provider can use this knowledge to guide initial dosing (with adjustment, as indicated based on response) if genetic testing is not feasible or warranted
Polypharmacy: Definition, challenges, and outcomes
treatment with multiple drugs
greatly increases the risk for interactions. Some of these interactions are negligible, but some can have life-threatening consequences. It is of crucial importance to ask the patient about all current drugs, including over-the-counter (OTC) medications and other herbal preparations. Many patients do not consider OTC or alternative pharmaceuticals as "medications" and may not mention them unless you ask specifically.
Acute Pain Management
Chronic Pain Management
Opioid Management
Regulations of Controlled Substances
The U.S. Department of Justice Drug Enforcement Agency (DEA) coordinates with local, state, and federal agents to reduce illicit drug use. The DEA enacted the Controlled Substances Act (CSA) in 1970 to regulate drugs and other substances based on their potential for abuse and dependency. Five schedules of controlled substances were created that are updated annually. Classes of scheduled substances include narcotics, depressants, stimulants, hallucinogens, and anabolic steroids. The DEA issues eligible providers with a registration number to write prescriptions for controlled substances. Characteristics of a valid DEA number include:
-The first letter identifies the type of provider: A=before 1985; B=after 1985; F=after 2007; M=nurse practitioner or physician assistant
-The 2nd letter the 1st letter of the provider's last name at the time of initial registration
Example: Tammy Greene applies for and receives a DEA number of MG2705208
M=nurse practitioner and G=Greene
Opioid Epidemic & Responsible Prescribing
Opioid Use Disorder
a pattern of use that leads to significant impairment or distress. Typically, this disorder is marked by unsuccessful efforts to reduce or control use resulting in the inability to fulfill work, school, or home responsibilities. Opioid use disorder is different from drug tolerance and physical dependence, which may also exist. Opioid use creates high levels of positive reinforcement, increasing the likelihood of continued use. It is often a chronic lifelong disorder, leading to serious consequences such as disability and death. Although it is similar to other substance use disorders, it has distinct features that have fueled the current opioid epidemic. Opioids can lead to physical dependence in only 4-8 weeks. Abruptly stopping use in chronic users leads to severe symptoms, which motivates continued use to prevent withdrawal. The 2016 CDC guidelines for prescribing opioids recommends calculating the total daily dose of opioids to help identify patients who might benefit from the reduction or tapering of opioids, given the risk of overdose
State Prescription Drug
Clinicians should review the patient's history of controlled substance prescriptions using state prescription drug monitoring program (PDMP) data to determine whether the patient is receiving opioid dosages or dangerous combinations that put him or her at high risk for overdose. Clinicians should review PDMP data when starting opioid therapy for chronic pain and periodically during opioid therapy for chronic pain, ranging from every prescription to every 3 months.
Monitoring Programs
safeguards to address the opioid public health crisis include prescription drug monitoring programs (PDMPs). These electronic databases enable providers to access information regarding a patient's prescription history of controlled substances. Nearly all states have implemented PDMPs, and some states require providers to check the PDMP before prescribing controlled substances. According to the CDC (2020), PDMPs have shown promising results in changing prescribing behaviors, decreasing the use of multiple providers by patients, and decreasing substance abuse treatment admissions.
Drug Schedules
Each drug preparation regulated under the CSA has been assigned to one of five categories: schedule I, II, III, IV, or V. Drugs in schedule I have a high potential for abuse and no approved medical use in the United States. In contrast, drugs in schedules II through V all have approved applications. Assignment to schedules II through V is based on abuse potential and potential for causing physical or psychological dependence. Of the drugs that have medical applications, those in schedule II have the highest potential for abuse and dependence. Drugs in the remaining schedules have decreasing abuse and dependence liabilities.
The therapeutic window
is the amount of a medication between the amount that gives an effect (effective dose) and the amount that gives more adverse effects than desired effects. For instance, medication with a small pharmaceutical window must be administered with care and control, e.g. by frequently measuring blood concentration of the drug, since it easily loses effects or gives adverse effects
Antagonist
A drug that attenuates the effect of an agonist. Can be competitive or non-competitive, each of which can be reversible or irreversible. A competitive antagonist binds to the same site as the agonist but does not activate it, thus blocks the agonist's action. A non-competitive antagonist binds to an allosteric (non-agonist) site on the receptor to prevent activation of the receptor. A reversible antagonist binds non-covalently to the receptor, therefore can be "washed out". An irreversible antagonist binds covalently to the receptor and cannot be displaced by either competing ligands or washing.
Agonist
A drug that binds to and activates a receptor. Can be full, partial or inverse. A full agonist has high efficacy, producing a full response while occupying a relatively low proportion of receptors. A partial agonist has lower efficacy than a full agonist. It produces sub-maximal activation even when occupying the total receptor population, therefore cannot produce the maximal response, irrespective of the concentration applied. An inverse agonist produces an effect opposite to that of an agonist, yet it binds to the same receptor binding-site as an agonist
Silent Antagonist
A drug that attenuates the effects of agonists or inverse agonists, producing a functional reduction in signal transduction. Affects only ligand-dependent receptor activation and displays no intrinsic activity itself. Also known as a neutral antagonist.
The duration of action of a drug
is the length of time that particular drug is effective. Duration of action is a function of several parameters including plasma half-life, the time to equilibrate between plasma and target compartments, and the off rate of the drug from its biological target.
Schedule I Drugs
Substances, or chemicals are defined as drugs with no currently accepted medical use and a high potential for abuse.
-heroin, LSD, marijuana, methylenedioxymethamphetamine (ecstasy), methaqualone, and peyote
Schedule II Drugs
Substances, or chemicals are defined as drugs with a high potential for abuse, with use potentially leading to severe psychological or physical dependence
All prescriptions for schedule II drugs must be typed or filled out in ink or indelible pencil and signed by the prescriber. Alternatively, prescribers may submit prescriptions using an electronic prescribing procedure. Oral prescriptions may be called in but only in emergencies, and a written prescription must follow within 72 hours. Prescriptions for schedule II drugs cannot be refilled. However, a DEA rule allows a prescriber to write multiple prescriptions on the same day—for the same patient and same drug
-combination products with less than 15 milligrams of hydrocodone per dosage unit.
-Vicoden, cocaine, methamphetamine, methadone, hydromorphone, meperidine, oxycodone, fentanyl, adderall, ritalin
Schedule III Drugs
Substances, or chemicals, are defined as drugs with a moderate to low potential for physical and psychological dependence. Less potential abuse than schedule I and II.
-Products containing less than 90 milligrams of codeine per dosage unit (tylenol with codeine), ketamine, anabolic steroids, testosterone.
Prescriptions for drugs in schedules III may be oral, written, or electronic. If authorized by the prescriber, these prescriptions may be refilled up to 5 times. Refills must be made within 6 months of the original order. If additional medication is needed beyond the amount provided for in the original prescription, a new prescription must be written
Schedule IV Drugs
Substances, or chemicals are defined as drugs with a low potential for abuse and low risk of dependence.
-Xanax, soma, darvon, darvocet, valium, ativan, ambien, tramadol
Prescriptions for drugs in schedules IV may be oral, written, or electronic. If authorized by the prescriber, these prescriptions may be refilled up to 5 times. Refills must be made within 6 months of the original order. If additional medication is needed beyond the amount provided for in the original prescription, a new prescription must be written
Schedule V Drugs
preparations containing limited quantities of certain narcotics. Used mainly for antidiarrheal, antitussives, and analegesic purposes.
-cough preparations with less than 200 milligrams of codeine or per 100 mililiters (robitussion AC), lomotil, motofen, lyrica, parepectolin
Effects of certain pain medications on the heart
How to assess patient's overdose risk
Use of benzodiazepines with opioids
Assessing and Addressing OUD
Determining whether to initiate opioids for chronic pain
Using PDMP to promote patient safety
Reducing the risks of opioids
Treating chronic pain without opioids
Nitrates
Nitroglycerin has been used to treat angina
Nitroglycerin decreases the pain of exertional angina primarily by decreasing cardiac oxygen demand. Oxygen demand is decreased as follows: by dilating veins, nitroglycerin decreases venous return to the heart and thereby decreases ventricular filling; the resultant decrease in wall tension (preload) decreases oxygen demand
Therapeutic Goal: Reduction of the frequency and intensity of anginal attacks.
Baseline Data: Frequency and intensity of anginal attacks and the factors that precipitate anginal attacks. Blood pressure and heart rate should be noted.
Monitoring: No routine blood monitoring necessary.
Identifying High-Risk Patients: Use with caution in hypotensive patients and in patients taking drugs that can lower blood pressure.
Evaluating Therapeutic Effects: Instruct patients to keep a record of the frequency and intensity of anginal attacks and the factors that precipitate these attacks.
Minimizing Adverse Effects: Use with phosphodiesterase type 5 inhibitors (sildenafil) is contraindicated.
Adverse effect-> headache
Beta-blockers
β blockers (e.g., propranolol, metoprolol) are first-line drugs for angina of effort, but are not effective against vasospastic angina
β blockers should not be used by patients with sick sinus syndrome, heart failure, or second-degree or third-degree AV block.
β blockers reduce anginal pain primarily by decreasing cardiac oxygen demand, principally through blockade of β1 receptors in the heart, which decreases heart rate and contractility.
β blockers should be used with caution by patients with asthma. If an asthmatic individual absolutely must use a β blocker, a β1-selective agent (e.g., metoprolol) should be chosen. β blockers can mask signs of hypoglycemia and therefore must be used with caution in patients with diabetes.
When starting or restarting sotalol, patients should be in a facility that can provide continuous electrocardiogram monitoring and cardiopulmonary resuscitation for a minimum of 3 days to minimize problems associated with induced arrhythmia.
Creatinine clearance should be established before initiating this drug.
Betapace cannot be substituted for Betapace AF when treating atrial fibrillation.
Therapeutic Goal: Principal indications are hypertension, angina pectoris, heart failure, and cardiac dysrhythmias. Indications for individual agents are shown in Table 16.5.
Baseline Data: Heart rate, blood pressure (supine, sitting, and standing depending on patient status), ECG (if indicated by patient age and status), and general cardiovascular status
Monitoring: Heart rate, blood pressure, evaluation for adverse effects (with symptom-focused assessment if indicated). Advise patients to record the incidence, circumstances, and severity of any symptoms that may indicate inadequate control of symptoms for which the drug is given (e.g., angina) or a new onset of adverse effects.
Identifying High-Risk Pat
Calcium Channel Blockers
The CCBs used most frequently are verapamil, diltiazem, and nifedipine (a dihydropyridine-type calcium channel blocker). Accordingly, our discussion focuses on these three drugs. All three can block calcium channels in VSM, primarily in arterioles.
Verapamil and Diltiazem
Therapeutic Goal: Verapamil and diltiazem are indicated for hypertension, angina, and cardiac dysrhythmias.
Baseline Data: Determine blood pressure and pulse rate and obtain laboratory evaluations of liver and kidney function.
Monitoring: No routine blood monitoring required.
Identifying High-Risk Patients: These drugs are contraindicated in patients with hypotension, sick sinus syndrome, and second- or third-degree atrioventricular block.
Evaluating Therapeutic Effects: Monitor blood pressure periodically. For angina, the patient should keep ongoing records of time and intensity of anginal attacks.
Minimizing Adverse Effects: Initiate therapy with low doses, adjust doses carefully, monitor weight loss daily, and use an intermittent dosing schedule.
Thiazide diuretics
thiazides increase renal excretion of sodium, chloride, potassium, and water
ACEI
ARB
Labetalol
Protype drug for heart failure
Statins
Statin Intensity
When to use each intensity statin
-cardiac case study
Non-statin therapy
Non-statin add-on drugs to statin therapy
antiplatelet agents
Anticoagulants
Colchincine
Allopurinol
Febuxostat
Indomethacin
Alendronate
Ibandronate
NSAIDs
DMARDs
Methotrexate
Lefluonomide
During what trimester is a pregnant woman most at risk for adverse drug reactions with potential long term consequences?
1st trimester (fetus most at risk d/t rapid growth)
What is BEERS criteria?
Recommendations of medications inappropriate for elderly (65 and older), prescriber ultimately decides
What is the CYP450 (cytochrome P450)
liver enzyme system where medications are metabolized, can either be inducers or inhibitors and create drug-drug interactions
CYP450 inducers
Speed up metabolism of drugs (drug is cleared faster), drug has lesser effect (decrease blood levels of drug), elevate CYP450 enzymes
CYP450 inducers pneumonic
"Bullshit Crap GPS INDUCES rage"
CYP450 inducer drug names
Barbituates, St John wort, Carbamazepine, rifampin, alcohol, phenytoin, griseofulvin, phenobarbital, sulfonylureas
CYP450 inhibitors
inhibit metabolism, increase blood levels of medications
CYP450 pneumonic
"VISA credit card debt INHIBITS spending on designers like CK to look GQ"
CYP450 inhibitors drug names
Valproate, isoniazid, sulfonamides, amiodarone, chloramphenicol, ketoconazole, grapefruit juice, quinidine
Physiological changes during pregnancy that impact pharmacodynamics and pharmacokinetic properties of drugs?
increase glomerular filtration rate leads to increase durg excretion
increase hepatic metabolism
decrease tone and motility of bowel
increase drug absorption
Examples of medications that can be teratogenic
Antiepileptic drugs, antimicrobials such as tetracyclines and fluoroquinolones, vitamin A in large doses, some anticoagulants, and hormonal medications such as diethylstilbestrol (DES).
How is absorption of intramuscular medications different in neonates?
slow and erratic due to low blood flow in muscles first few days of life
Why is absorption of medication in the stomach increased in infancy?
delayed gastric emptying
Some medications that should be avoided in the pediatric patient?
glucocorticoids, discoloration of developing teeth with tetracyclines, and kernicterus with sulfonamides, levofloxacin (antibiotics)
aspirin (Severe intoxication from acute overdose)
what should be included in medication administration patient education?
dosage size and timing
route and technique of administration
duration of treatment
drug storage
nature and time course of desired responses
nature and time course of adverse responses
finish taking antibiotic
What are some things that put the elderly patient at higher risk for adverse drug reactions?
reduced renal function
polypharmacy (the use of five or more medications daily)
greater severity of illness
presence of comorbidities
use of drugs that have a low therapeutic index (e.g., digoxin)
increased individual variation secondary to altered pharmacokinetics
inadequate supervision of long-term therapy
poor patient adherence
How can healthcare providers decrease likelihood of an elderly patient experiencing an adverse drug reaction?
obtaining a thorough drug history that includes over-the-counter medications
considering pharmacokinetic and pharmacodynamics changes due to age
monitoring the patient's clinical response and plasma drug levels
using the simplest regimen possible
monitoring for drug-drug interactions and iatrogenic illness
periodically reviewing the need for continued drug therapy
encouraging the patient to dispose of old medications
taking steps to promote adherence and to avoid drugs on the Beers list
How can we promote medication adherence with elderly patients?
simplifying drug regimens
providing clear and concise verbal and written instructions
using an appropriate dosage form
clearly labeling and dispensing easy-to-open containers
developing daily reminders
monitoring frequently
affordability of drugs
support systems
Why do nitrates need to be taken no later than 4 PM?
Need nitrate free interval so tolerance doesn't develop
Nine factors that impact outcome of medication?
Gender and race
Genetics and pharmacogenomics
Variability in absorption
placebo effect
Tolerance
patho
age
bodyweight
Do you need informed consent for genetic testing?
yes
What is the purpose of the Genetic Information Non-Discriminatory Act?
Protects patients from discrimination by employers and insurance providers based on genetic information
Difference between practice authority and prescriptive authority?
Practice authority refers to the nurse practitioner's ability to practice without physician oversight, whereas prescriptive authority refers to the nurse practitioner's authority to prescribe medications independently and without limitations.
Who regulates prescriptive authority?
the jurisdiction of a health professional board. This may be the State Board of Nursing, the State Board of Medicine, or the State Board of Pharmacy, as determined by each state.
What is scope of practice determined by?
is determined by state practice and licensure laws.
What is full practice authority?
Nurse practitioners have the autonomy to evaluate patients, diagnose, order and interpret tests, initiate and manage treatments and prescribe medications, including controlled substances without physician oversight.
What is reduced practice authority?
Nurse practitioners are limited in at least one element of practice. The state requires a formal collaborative agreement with an outside health discipline for the nurse practitioner to provide patient care. ex/ physician involvement for 5 yrs than independent
What is restricted practice authority?
Nurse practitioners are limited in at least one element of practice by requiring supervision, delegation, or team management by an outside health discipline for the nurse practitioner to provide patient care.- typically doctor on site
What are components of Rx?
Prescriber Contact info
Prescribers name
NPI
DEA
Patient name
DOB
Date
Allergies
Medication name
Strength
Quantity
Indication for use
Direction for use
Refills
Signature
What are some potential problems that arise with written prescriptions?
Must contain all elements
May have pre-populated information
Write legibly
Avoid error prone abbreviations
Tamper resistant scripts are often required
Reasons for monitoring drug therapy
determining therapeutic dosage
evaluating medication adequacy
identifying adverse effects
serious or life-threatening risks.
Which schedules of drugs can APRNs prescribe?
depends on state - most II-V
How does limited prescriptive authority impact patients within the healthcare system?
longer wait times to sign a prescription
limits practitioners that are needed in rural areas
unequal relationships between providers. Ex. one has more power
high need for providers due to lack of providers and high amounts of patients.
Independent practitioners= more patients being seen= lessens the patient/provider load
Provider key responsibilities when prescribing?
safe and competent practice
understanding of the drugs, reactions, and pharmacology
Be aware of the age group you are prescribing to
Ex. Children vs older adults
What should be used to make prescribing decisions?
documented provider-patient relationship, not prescribing for family or friends, documenting a thorough H&P, including discussions with the patient, drug monitoring/titrating.
cost, guidelines, availability, interactions, side effects, allergies, hepatic and renal function, need for monitoring, and special populations
What happens when someone has a poor metabolism phenotype?
medications metabolized slower, medication might not work or put them at risk for side-effects
What does the US food and drug administration regulate when it comes to medications?
Whether the drug is safe, effective, and benefits of a drug outweigh the risks
reasons for medication non-adherence
patients never filling/refilling prescriptions (resulting in therapeutic failure)
multiple chronic disorders
multiple prescription medications
multiple doses per day for each medication
drug packaging that is difficult to open
multiple prescribers
changes in the regimen (adding meds, changes in dose or timing)
cognitive or physical impairment (reduction in memory, hearing, visual, color, or manual dexterity)
living alone
recent discharge from hospital
low literacy
inability to pay for meds
personal conviction that a drug is unnecessary or the dosage is too high
presence of side effects